Switzerland Faces Economic Threat from US Tariffs: 100,000 Jobs on the Line

The US has imposed a 39% customs duty on Swiss exports, including pharmaceutical products, due to the trade deficit between the two countries. Economiesuisse warns that this could affect up to 100,000 Swiss jobs across key export sectors, with 20,000 in electronics, 14,200 in food and tobacco, and 13,900 in pharmaceuticals. The Swiss government is working with companies to find ways through these tariffs and urging politicians to improve framework conditions in Switzerland to offset the competitive disadvantage.

The United States has imposed a 39% customs duty on Swiss exports, including pharmaceutical products, due to the trade deficit between the two countries. This move has sparked concerns about the potential impact on the Swiss economy and job market. Economiesuisse, a Swiss business federation, has warned that this could affect up to 100,000 Swiss jobs across key export sectors, with 20,000 in electronics, 14,200 in food and tobacco, and 13,900 in pharmaceuticals [3].

The Swiss government is actively working to mitigate the effects of these tariffs. Officials are engaging in dialogues with U.S. authorities to find ways to navigate the steep tariffs. Economiesuisse has called on political leaders to "quickly and effectively lighten the administrative and regulatory burden on companies" and to "offset the competitive disadvantage on the US market by improving the framework conditions in Switzerland" [2].

The pharmaceutical industry, a significant contributor to Swiss exports, remains exempt from the current 39% tariff. However, U.S. President Donald Trump has threatened to hike tariffs up to 250% if pharmaceutical companies do not reduce their drug prices [2]. This threat looms over the industry, adding uncertainty to an already volatile market.

Despite these challenges, Swiss pharmaceutical companies have already begun to invest heavily in the U.S. to head off steeper trade penalties. Novartis, for instance, has announced a $23 billion plan to build and expand 10 facilities, while Roche has committed $50 billion over five years, promising more than 12,000 new jobs [1].

Retail sentiment on Stocktwits indicates a mixed outlook for Roche and Novartis. While Roche faces a "bearish" outlook, Novartis has drawn a "bullish" outlook, reflecting the differing perceptions of the companies' ability to navigate the trade challenges [1].

The Swiss government's efforts and the industry's investments aim to cushion the impact of the tariffs. However, the long-term effects on the Swiss economy and job market remain uncertain. The situation underscores the importance of ongoing dialogue and cooperation between Switzerland and the United States to address the trade deficit and mitigate potential negative consequences.

References:
[1] https://newsable.asianetnews.com/markets/novartis-rides-bullish-retail-mood-roche-faces-gloom-amid-swiss-us-trade-concerns-articleshow-gqcdxb4
[2] https://economictimes.indiatimes.com/news/international/us/swiss-job-losses-due-to-trump-tariffs-2025-switzerland-us-trade-war-tariffs-impact-latest-news/articleshow/123372955.cms
[3] https://www.swissinfo.ch/eng/global-trade/customs-duties-threaten-100000-jobs-in-switzerland/89845237